Publication type
Journal Article
Authors
- Carolina Bonilla
- Sarah J. Lewis
- Mari-Anne Rowlands
- Tom R. Gaunt
- George Davey Smith
- David Gunnell
- Tom Palmer
- Jenny L. Donovan
- Freddie C. Hamdy
- David E. Neal
- Rosalind Eeles
- Doug Easton
- Zsofia Kote-Jarai
- Ali Amin Al Olama
- Sara Benlloch
- Kenneth Muir
- Graham G. Giles
- Fredrik Wiklund
- Henrik Gronberg
- Christopher A. Haiman
- Johanna Schleutker
- Børge G. Nordestgaard
- Ruth C. Travis
- Nora Pashayan
- Kay-Tee Khaw
- Janet L. Stanford
- William J. Blot
- Stephen Thibodeau
- Christiane Maier
- Adam S. Kibel
- Cezary Cybulski
- Lisa Cannon-Albright
- Hermann Brenner
- Jong Park
- Radka Kaneva
- Jyotsna Batra
- Manuel R. Teixeira
- Hardev Pandha
- Mark Lathrop
- Richard M. Martin
- Jeff M. P. Holly
Publication date
October 15, 2016
Summary:
Circulating insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are associated with prostate cancer. Using genetic variants as instruments for IGF peptides, we investigated whether these associations are likely to be causal. We identified from the literature 56 single nucleotide polymorphisms (SNPs) in the IGF axis previously associated with biomarker levels (8 from a genome-wide association study [GWAS] and 48 in reported candidate genes). In ∼700 men without prostate cancer and two replication cohorts (N ∼ 900 and ∼9,000), we examined the properties of these SNPS as instrumental variables (IVs) for IGF-I, IGF-II, IGFBP-2 and IGFBP-3. Those confirmed as strong IVs were tested for association with prostate cancer risk, low (< 7) vs. high (≥ 7) Gleason grade, localised vs. advanced stage, and mortality, in 22,936 controls and 22,992 cases. IV analysis was used in an attempt to estimate the causal effect of circulating IGF peptides on prostate cancer. Published SNPs in the IGFBP1/IGFBP3 gene region, particularly rs11977526, were strong instruments for IGF-II and IGFBP-3, less so for IGF-I. Rs11977526 was associated with high (vs. low) Gleason grade (OR per IGF-II/IGFBP-3 level-raising allele 1.05; 95% CI: 1.00, 1.10). Using rs11977526 as an IV we estimated the causal effect of a one SD increase in IGF-II (∼265 ng/mL) on risk of high vs. low grade disease as 1.14 (95% CI: 1.00, 1.31). Because of the potential for pleiotropy of the genetic instruments, these findings can only causally implicate the IGF pathway in general, not any one specific biomarker.
Published in
International Journal of Cancer
Volume and page numbers
Volume: 139 , p.1 -1
DOI
http://dx.doi.org/10.1002/ijc.30206
ISSN
207136
Subjects
Notes
© 2016 UICC
Open Access
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
#523703